G1 Therapeutics - GTHX Stock Forecast, Price & News

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for G1 Therapeutics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" GTHX shares.
View GTHX analyst ratings or view top-rated stocks.

6 Wall Street research analysts have issued 12-month price targets for G1 Therapeutics' shares. Their GTHX share price forecasts range from $10.00 to $35.00. On average, they predict the company's stock price to reach $27.00 in the next year. This suggests a possible upside of 263.4% from the stock's current price.
View analysts price targets for GTHX or view top-rated stocks among Wall Street analysts.

G1 Therapeutics' stock was trading at $5.43 at the beginning of 2023. Since then, GTHX stock has increased by 36.8% and is now trading at $7.43.
View the best growth stocks for 2023 here.

G1 Therapeutics saw a increase in short interest in the month of January. As of January 15th, there was short interest totaling 3,090,000 shares, an increase of 20.2% from the December 31st total of 2,570,000 shares. Based on an average daily volume of 1,160,000 shares, the short-interest ratio is currently 2.7 days.
View G1 Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 22nd 2023.
View our GTHX earnings forecast.

G1 Therapeutics, Inc. (NASDAQ:GTHX) posted its quarterly earnings results on Wednesday, November, 2nd. The company reported ($0.59) earnings per share for the quarter, beating analysts' consensus estimates of ($0.64) by $0.05. The firm earned $23.58 million during the quarter, compared to analysts' expectations of $22.64 million. G1 Therapeutics had a negative trailing twelve-month return on equity of 172.97% and a negative net margin of 328.58%.

Based on aggregate information from My MarketBeat watchlists, some companies that other G1 Therapeutics investors own include Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), Johnson & Johnson (JNJ), Gilead Sciences (GILD), Kadmon (KDMN), VBI Vaccines (VBIV), Novavax (NVAX) and Pfizer (PFE).

(GTHX) raised $101 million in an IPO on Wednesday, May 17th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Cowen and Company served as the underwriters for the IPO and Needham & Company and Wedbush PacGrow were co-managers.

G1 Therapeutics trades on the NASDAQ under the ticker symbol "GTHX."

G1 Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Andrew Perry, Glenn P Muir, James S Hanson, Jennifer K Moses, John E (Jack) Jr Bailey, Mark A Velleca, Mark A Velleca, Rajesh Malik, Seth Rudnick and Terry L Murdock.
View institutional ownership trends.

Shares of GTHX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of GTHX stock can currently be purchased for approximately $7.43.

G1 Therapeutics (NASDAQ:GTHX) has a market capitalization of $318.84 million and generates $46.85 million in revenue each year. The company earns $-148,350,000.00 in net income (profit) each year or ($3.60) on an earnings per share basis.

The company employs 148 workers across the globe.

G1 Therapeutics' mailing address is 700 Park Offices Drive Suite 200, Research Triangle Park NC, 27709. The official website for the company is www.g1therapeutics.com. The company can be reached via phone at (919) 213-9835, via email at jmacdonald@g1therapeutics.com, or via fax at 919-741-5830.